At the end of experiment, AAV1‐shALDH2 administration resulted in an increased cumulative survival rate (Figure S5L, Supporting Information) and reduced AAA incidence (30.0%) more dramatically compared with AAV1‐scramble (AAA incidence of 63.6%) after Ang II infusion (Figure S5M,N, Supporting Information). The gene discussed is AGT; the disease is triple-A syndrome.